A new virtual conference will explore how artificial intelligence (AI) can help healthcare providers and scientists efficiently analyze vast amounts of data and make more informed decisions, the Endocrine Society announced today. The Society will host its first-ever Artificial Intelligence in Healthcare Virtual Summit Nov. 8-9. The event will explore AI’s potential to revolutionize patient...
Injectable and gel versions of testosterone replacement therapy have long been considered cumbersome by both patients and providers, for a litany of reasons from being difficult to administer to an overwhelming insurance burden. However, research from ENDO 2024 revealed that a new oral therapy could potentially eliminate these barriers and be a safer option. By...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * TEPEZZA Receives Approval in Japan to Treat TED On Sept. 24, Amgen announced that TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high clinical activity score (CAS) thyroid eye disease (TED) by Japan’s Ministry of Health, Labour and Welfare (MHLW)....
Pregnant Women With SSD May Have Children with Developmental Delays
Pregnant women who do not get enough sleep may be at higher risk of having children with neurodevelopmental delays, according to new research published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Short sleep duration (SSD) is defined as sleeping less than seven hours per night. Pregnant woman may have trouble sleeping due...
Endocrine Society Members Win 2024 Lasker~DeBakey Clinical Medical Research Award
Three Endocrine Society members have taken home the 2024 Lasker~DeBakey Clinical Medical Research Award. Joel F. Habener, MA, MD, chief of Laboratory of Molecular Endocrinology, Massachusetts General Hospital; Lotte Bjerre Knudsen, DMSc, chief scientific advisor and head of the GLP-1 Centre of Excellence at Novo Nordisk; and Svetlana Mojsov, PhD, research associate professor at Rockefeller...
Lorenzo Smith Receives FASEB’s Howard Garrison Advocacy Fellowship
Endocrine Society member Lorenzo Smith, a PhD candidate at the Huntsman Cancer Institute at the University of Utah, has been selected as a Howard Garrison Advocacy Fellow through the Federation of American Societies for Experimental Biology (FASEB). This program is designed to train and support scientists seeking opportunities to learn more about the policymaking process...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Neuroendocrine Tumor Treatment Data Presented by Exelixis On September 16, Exelixis announced updated and final data from CABINET, a Phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort with...
Review Examines Cardiometabolic Aspects of Congenital Adrenal Hyperplasia
A paper recently published in Endocrine Reviews takes a look at the cardiometabolic risk in patients with congenital adrenal hyperplasia (CAH), since patients with CAH who are being treated still face numerous complications and increased mortality. The authors of the review (Krysiak et al) write that the aim of their article is to create an...
